1874-42-6

Usage

Uses

Used in Biochemical Research:
2-(2-Methoxyphenyl)-5-phenyl-1,3,4-oxadiazole is used as a fluorescent probe for detecting metal ions in biological systems. Its ability to selectively bind and fluoresce in the presence of specific metal ions makes it a valuable tool for studying metal ion interactions and their roles in biological processes.
Used in Anti-inflammatory Applications:
In the pharmaceutical industry, 2-(2-Methoxyphenyl)-5-phenyl-1,3,4-oxadiazole is used as a potential anti-inflammatory agent. Research has shown its ability to inhibit the production of inflammatory cytokines, which play a crucial role in the inflammatory response. This property makes it a promising candidate for the development of new anti-inflammatory drugs.
Used in Photodynamic Therapy:
In the field of cancer treatment, 2-(2-Methoxyphenyl)-5-phenyl-1,3,4-oxadiazole has been studied for its potential application as a photosensitizer in photodynamic therapy. Its ability to absorb light and generate reactive oxygen species upon illumination makes it a candidate for targeted cancer cell destruction, offering a non-invasive and minimally invasive treatment option for various types of cancer.

InChI:InChI=1/C15H12N2O2/c1-18-13-10-6-5-9-12(13)15-17-16-14(19-15)11-7-3-2-4-8-11/h2-10H,1H3

Upstream product

• 6781-63-1 1-benzoyl-2-(2-methoxybenzoyl)hydrazine 
• 86268-08-8 2-methoxy-benzoic acid benzylidenehydrazide 
• 7466-54-8 2-methoxybenzoylhydrazine 
• 65-85-0 benzoic acid 
• 21615-34-9 2-Methoxybenzoyl chloride 
• 613-94-5 benzoic acid hydrazide 
• 579-75-9 2-Methoxybenzoic acid 
• 71112-99-7 N’-(2-methoxyphenylmethylene)benzohydrazide 
• 135-02-4 ortho-anisaldehyde 
• 18039-42-4 5-phenyl-2H-1,2,3,4-tetrazole 
• 67-66-3 chloroform 
• 529-28-2 4-iodoanisol 
• 100-47-0 benzonitrile 
• 91098-98-5 N’-benzoyl-2-methoxybenzohydrazine 

Downstream Products

• 18233-24-4 2-(5-phenyl-1,3,4-oxadiazol-2-yl)phenol 
• 1642111-06-5 2-(5-phenyl-1,3,4-oxadiazol-2-yl)phenol potassium salt 

Relevant academic research and scientific papers

The preparation, characterization and catalytic activity of Ni NPs supported on porous alginate-g-poly(p-styrene sulfonamide-co-acrylamide)

Herein, we report the synthesis of nickel nanoparticles under mild conditions using porous alginate-g-poly(p-styrene sulfonamide-co-acrylamide) as a protecting/stabilizing agent and sodium borohydride as a reducing agent. The porous cross-linked polymeric support was preparedviacombining the use of sol-gel, nanocasting, and crosslinking techniques, in which thep-styrene sulfonamide monomer (PSSA) andN,N′-methylene-bis (acrylamide) (MBA) cross-linker underwent copolymerization on the surface of sodium alginate in the presence of a SiO2nanoparticle (NP) template (Alg-PSSA-co-ACA). The prepared catalyst (Alg-PSSA-co-ACA@Ni) showed high catalytic activity for the one-step synthesis of 1,3,4-oxadiazoles from the reaction of hydrazides and aryl iodides through isocyanide insertion/cyclization.

UV-Induced 1,3,4-Oxadiazole Formation from 5-Substituted Tetrazoles and Carboxylic Acids in Flow

A range of 1,3,4-oxadiazoles have been synthesized using a UV-B activated flow approach starting from carboxylic acids and 5-substituted tetrazoles. The application of UV light represents an attractive alternative to the traditional thermolytic approach and has demonstrated comparable efficiency and versatility, with a diverse substrate scope, including the incorporation of highly substituted amino acids.

Efficient green photoluminescence and electroluminescence of iridium complexes with high electron mobility

Aiming to balance the injection and transport of electrons and holes, nitrogen heterocycle and 1,3,4-oxadiazole derivatives were introduced in iridium(iii) complexes to obtain organic light-emitting diodes (OLEDs) with high performances. Thus, two novel Ir(iii) complexes (Ir(tfmphpm)2(pop) and Ir(tfmppm)2(pop)) with green emissions using 2-(3,5-bis(trifluoromethyl)phenyl)pyrimidine (tfmphpm) and 2-(2,6-bis(trifluoromethyl)pyridin-4-yl)pyrimidine (tfmppm) as cyclometalating ligands, and 2-(5-phenyl-1,3,4-oxadiazol-2-yl)phenol (pop) as an ancillary ligand were synthesized. Both emitters show high photoluminescence efficiencies up to 94% and good electron mobility. The devices using two emitters with the structure of ITO (indium-tin-oxide)/MoO3 (molybdenum oxide, 5 nm)/TAPC (di-[4-(N,N-ditolyl-amino)-phenyl]cyclohexane, 30 nm)/mCP (1,3-bis(9H-carbazol-9-yl)benzene, 5 nm)/Ir(iii) complexes (6 wt%):PPO21 (3-(diphenylphosphoryl)-9-(4-(diphenylphosphoryl)phenyl)-9H-carbazole, 10 nm)/TmPyPB (1,3,5-tri(m-pyrid-3-yl-phenyl) benzene, 40 nm)/LiF (1 nm)/Al (100 nm) display good electroluminescence performances with a maximum luminance of 48981 cd m2, a maximum current efficiency of 92.79 cd A1 and a maximum external quantum efficiency up to 31.8%, respectively, and the efficiency roll-off ratio is low, suggesting that they have potential application in OLEDs.

Orange red iridium complexes with good electron mobility and mild OLED efficiency roll-off

Two iridium(III) complexes with 1-(3,5-bis(trifluoromethyl)-pyridin-4-yl)isoquinoline (tntpiq) as main ligand, 2-(5-pyridin-4-yl)-1,3,4-oxadiazol-2-yl)phenol (pop) and 2-(5-pyridin-4-yl)-1,3,4-thiadiazol-2-yl)phenol (psp) as ancillary ligands were investigated. Both complexes emit orange red lights with different photoluminescence efficiencies (Ir(tntpiq)2(pop): λem = 585 nm, Φ = 0.41 and Ir(tntpiq)2(psp): λem = 590 nm, Φ = 0.59). Moreover, the electron mobility values of the two complexes are higher than that of the electron transport material Alq3 (tris(8-hydroxyquinoline)aluminium), which are beneficial for their performances in organic light-emitting diodes (OLEDs). The devices with a structure of ITO/MoO3 (3 nm)/TAPC (1,1-bis[4-[N,N-di(p-tolyl)amino]pyridin-4-yl]cyclohexane, 30 nm)/Ir(III) complexes (2 wt%): 26DCzPPy (2,6-bis(3-(carbazol-9-yl)pyridin-4-yl)pyridine, 10 nm)/TmPyPB (1,3,5-tri(m-pyrid-3-yl-pyridin-4-yl)benzene, 40 nm)/LiF (1 nm)/Al (100 nm) displayed similar performances with a maximum current efficiency of 24.3 cd A?1 and a maximum external quantum efficiency of 11.6%, respectively, and the efficiency roll-off is very mild.

Photocatalyzed facile synthesis of 2,5-diaryl 1,3,4-oxadiazoles with polyaniline-?g-C3N4-TiO2 composite under visible light

PANI (polyaniline)-g-C3N4-TiO2 composite was prepared and found to be efficient for the synthesis of 2,5-diaryl 1,3,4-oxadiazoles under visible light. This reaction involved decarboxylation and cyclization from α-keto acids with acylhydrazines, and a broad scope of substrates were tolerated to provide the desired products in moderate to good yields. Control experiments indicated that a radical pathway was involved in the present photocatalytic reaction and a synergistic effect may exist in the ternary composite. Moreover, this semiconductor photocatalyst could be readily recovered and showed good reusability with only slight decrease in the catalytic activity after six consecutive runs.

Application of compound in preparation of kallikrein KLK7 inhibition medicines, and synthesis method of compound

The invention belongs to the field of biomedicines, and especially relates to an application of a compound in the preparation of kallikrein KLK7 inhibition medicines, and a synthesis method of the compound. The structural formula of the compound is shown in the description. The compound for inhibiting the kallikrein KLK7 can effectively inhibit the activity of the KLK7, the synthesis method of the compound is simple and is easy to implement, and proper auxiliary materials and assistants can be added to prepare medicinal preparations for inhibiting the activity of the KLK7.

Efficient Electroluminescence of Two Heteroleptic Platinum Complexes with a 2-(5-Phenyl-1,3,4-oxadiazol-2-yl)phenol Ancillary Ligand

Two new platinum(II) cyclometalated complexes with 2-phenylpyridine (Pt1) and 2-(4-trifluoromethyl)phenylpyridine (Pt2) as the main ligands and 2-(5-phenyl-1,3,4-oxadiazol-2-yl)phenol (pop) as the electron-transporting ancillary ligand were developed. The photoluminescence quantum efficiency yields of both green Pt1 and Pt2 phosphors (λmax 490 and 496 nm) are 20.0% and 31.0% in CH2Cl2 solutions, respectively. Efficient OLEDs (organic light emitting diodes) of ITO/TAPC (bis[4-(N,N-ditolylamino)phenyl]cyclohexane, 40 nm)/Pt1 or Pt2 (5 wt %):TCTA (4,4′,4″-tri(carbazoyl-9-yl)triphenylamine, 10 nm)/Pt1 or Pt2 (5 wt %):2,6DCzPPy (2,6-bis(3-(carbazol-9-yl)phenyl)pyridine, 10 nm)/TmPyPB (1,3,5-tris(m-pyrid-3-ylphenyl)benzene, 40 nm)/LiF (1 nm)/Al (100 nm) were fabricated. Particularly, device G1 based on complex Pt1 with 5 wt % doped concentration showed superior performance with a maximum current efficiency (ηmax,c) of 55.6 cd A-1, a maximum power efficiency (ηmax,p) of 52.2 lm W-1, and a maximum external quantum efficiency (EQEmax) of 18.0%. Device G2 with the Pt2 emitter displayed lower efficiency rolloff with ηc values of 48.5 and 43.1 cd A-1 as the luminance reached 5000 and 10000 cd m-2, respectively. These research results demonstrate that the Pt(II) complexes with an ancillary ligand attached with the 1,3,4-oxadiazole group have promising applications in efficient OLEDs.

Application of compound to preparation of medicine for inhibiting kallikrein KLK7 and synthesis method of compound

The invention belongs to the field of biomedicine and particularly relates to application of a compound to preparation of a medicine for inhibiting kallikrein KLK7 and a synthesis method of the compound. The compound is used for preparing the medicine for inhibiting kallikrein KLK7. The structural formula of the compound is as shown in the description. The compound for inhibiting kallikrein KLK7 can effectively inhibit the activity of KLK7, the synthesis method is easy to implement, and proper auxiliary materials and assistant are added so that the compound can be prepared into medicine preparations for inhibiting the activity of KLK7.

Application and synthetic method of compound in the preparation of a medicine for inhibiting kallikrein KLK7

The invention belongs to the field of biomedicine, and in particular to application and synthetic method of a compound in the preparation of a medicine for inhibiting kallikrein KLK7. The invention provides application of a compound in the preparation of a medicine for inhibiting kallikrein KLK7. The structural formula of the compound is shown as below. The compound for inhibiting kallikrein KLK7 release can effectively inhibit the KLK7 activity. The synthesis method is simple and easy; and suitable excipients and additives can be added to prepare a medicament preparation for inhibiting the activity of KLK7.

Application of compound in preparing medicine for inhibiting kallikrein (KLK7) and synthetic method of compound

The invention belongs to the field of biomedicine, and particularly relates to application of a compound in preparing medicine for inhibiting kallikrein (KLK7) and a synthetic method of the compound. According to the application of the compound in preparing medicine for inhibiting KLK7, the structural formula of the compound is shown in the description. The compound for inhibiting KLK7 can effectively inhibit the activity of KLK7; the synthetic method of the compound is simple and easy to implement, and the compound can be prepared into a pharmaceutical preparation for inhibiting the activity of KLK7 by adding proper accessories and auxiliaries.